Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific,Abcam,AB209538
Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Dot blot, ICC/IF, IHC-P in human, mouse, rat samples. Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538) has been cited over 73 times in peer reviewed journals and is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-Alpha-synuclein aggregate antibody (Anti-SNCA antibody) [MJFR-14-6-4-2] - Conformation-Specific (ab209538) has 6 independent reviews from customers. Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538) specifically detects Alpha-synuclein aggregate (UniProt ID: P37840; Molecular weight: 14kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone MJFR-14-6-4-2 - ab214033 . Antibody clone MJFR-14-6-4-2 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 488, Alexa Fluor® 647, Biotin, Alexa Fluor® 594 ( ab216124 , ab216309 , ab227047 , ab283628 ). Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538) was developed by Abcam in partnership with the Michael J. Fox Foundation for Parkinson's Research. ab209538 is not suitable for WB or other denaturing conditions, as it is conformation-specific. This antibody is useful for studying Parkinson's disease and other synucleinopathies including dementia with Lewy bodies and multiple system atrophy. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Collaborations This antibody was developed with support from The Michael J. Fox Foundation.
Host
Rabbit
Reactivity
Mouse, Rat, Human
Application
Dot, IHC-P, ICC/IF
Platform ID
BAB513254193
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data The protein expressed by the SNCA gene is involved in various synaptic activities, including the regulation of synaptic vesicle trafficking and neurotransmitter release. As a monomer, it enhances synaptic vesicle exocytosis through vesicle priming, fusion, and dilation of exocytotic fusion pores. Mechanistically, it increases local Ca(2+) release, which is crucial for ATP-induced exocytosis. In its multimeric membrane-bound form, SNCA acts as a molecular chaperone, assisting in the folding of synaptic fusion components known as SNAREs at the presynaptic plasma membrane, in conjunction with cysteine string protein-alpha/DNAJC5, a function that is vital for maintaining normal SNARE-complex assembly during aging. Additionally, SNCA plays a role in dopamine neurotransmission regulation by associating with the dopamine transporter (DAT1) and modulating its activity. This supplementary information is collated from multiple sources and compiled automatically. See full target information SNCA
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.